Literature DB >> 12595413

Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model.

Hazeline Roche1, Anders Håkansson, Susan K Hollingshead, David E Briles.   

Abstract

Pneumococcal surface protein A (PspA) can elicit protection against Streptococcus pneumoniae in mouse infection models. PspA is classified by serology and amino acid sequence into two major families that are divided by sequence into five clades. The most variable portion of the molecule is the alpha-helical domain, which comprises the N-terminal half of PspA. Prior studies of a family 1 PspA protein observed that protective antibodies are reactive with epitopes in the alpha-helical domain and that most cross-protective epitopes mapped to the 108 most C-terminal amino acids of the alpha-helical region. In these studies, we have used six overlapping recombinant fragments of family 2, clade 3 PspA/EF3296 to map the protection-eliciting regions of its alpha-helical domain. The three fragments, which included the 104 most C-terminal amino acids of the alpha-helical domain (314 to 418), could each elicit protection against EF3296. A fragment comprising amino acids 75 to 305 failed to elicit significant protection. A fragment containing amino acids 1 to 115 elicited protection against EF3296 in BALB/c mice but not in CBA/N mice. All three fragments containing amino acids 314 to 418 were able to elicit cross-protection against pneumococci expressing PspA proteins of clades 2, 3, 4, and 5. Cross-protection elicited by these three fragments was easier to demonstrate in CBA/N mice than in BALB/c mice. The 1-to-115 fragment, however, elicited some cross-protection against clades 2 and 4 in BALB/c mice but not in CBA/N mice. These studies provide support for the importance of the C-terminal 104 and N-terminal 115 amino acids of the alpha-helical region of PspA in the elicitation of cross-protection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595413      PMCID: PMC148823          DOI: 10.1128/IAI.71.3.1033-1041.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Cross-reactive protection eliciting epitopes of pneumococcal surface protein A.

Authors:  B A Ralph; D E Briles; L S McDaniel
Journal:  Ann N Y Acad Sci       Date:  1994-08-15       Impact factor: 5.691

2.  Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis.

Authors:  J Yother; D E Briles
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

3.  Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.

Authors:  M J Crain; W D Waltman; J S Turner; J Yother; D F Talkington; L S McDaniel; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

Authors:  D E Briles; S K Hollingshead; J King; A Swift; P A Braun; M K Park; L M Ferguson; M H Nahm; G S Nabors
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

5.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

6.  Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum.

Authors:  I S Aaberge; J Eng; G Lermark; M Løvik
Journal:  Microb Pathog       Date:  1995-02       Impact factor: 3.738

7.  Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260.

Authors:  L S McDaniel; B A Ralph; D O McDaniel; D E Briles
Journal:  Microb Pathog       Date:  1994-11       Impact factor: 3.738

8.  Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies.

Authors:  L S McDaniel; G Scott; K Widenhofer; J M Carroll; D E Briles
Journal:  Microb Pathog       Date:  1986-12       Impact factor: 3.738

9.  Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA.

Authors:  J Yother; J M White
Journal:  J Bacteriol       Date:  1994-05       Impact factor: 3.490

10.  Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice.

Authors:  R C Tart; L S McDaniel; B A Ralph; D E Briles
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

View more
  26 in total

Review 1.  The host immune dynamics of pneumococcal colonization: implications for novel vaccine development.

Authors:  M Nadeem Khan; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Directed vaccination against pneumococcal disease.

Authors:  Yi Li; Andrew Hill; Marie Beitelshees; Shuai Shao; Jonathan F Lovell; Bruce A Davidson; Paul R Knight; Anders P Hakansson; Blaine A Pfeifer; Charles H Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

3.  Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.

Authors:  Dennis O Gor; Xuedong Ding; David E Briles; Michael R Jacobs; Neil S Greenspan
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

4.  A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.

Authors:  Jinfei Yu; Xiaorui Chen; Bo Li; Tiejun Gu; Xiangyu Meng; Wei Kong; Yongge Wu
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

5.  Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

Authors:  Adriana T Moreno; Maria Leonor S Oliveira; Daniela M Ferreira; Paulo L Ho; Michelle Darrieux; Luciana C C Leite; Jorge M C Ferreira; Fabiana C Pimenta; Ana Lúcia S S Andrade; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

6.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

7.  Identification of glycosylated regions in pneumococcal PspA conjugated to serotype 6B capsular polysaccharide.

Authors:  Giovana Cappio Barazzone; Vittoria Pinto; Danilo Donnarumma; Martha Massako Tanizaki; Nathalie Norais; Francesco Berti
Journal:  Glycoconj J       Date:  2014-04       Impact factor: 2.916

8.  Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

Authors:  Shannon L Haughney; Latrisha K Petersen; Amy D Schoofs; Amanda E Ramer-Tait; Janice D King; David E Briles; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2013-06-14       Impact factor: 8.947

9.  Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.

Authors:  Martina M Ochs; William Bartlett; David E Briles; Bryony Hicks; Audra Jurkuvenas; Peggy Lau; Bing Ren; Amanda Millar
Journal:  Microb Pathog       Date:  2007-10-11       Impact factor: 3.738

10.  Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae.

Authors:  Hazeline Roche; Bing Ren; Larry S McDaniel; Anders Håkansson; David E Briles
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.